F10 and adenoviridae infectious disease: HAdV-C5 is known to interact with coagulation factor X (FX) in blood, via the hexon protein, which mediates transduction of the liver and resulting in hepatotoxicity.16, 17, 18 High levels of HAdV-C5 pre-existing immunity in some populations may reduce the clinical efficacy of potential HAdV-C5-based oncolytic virotherapies,19, 20, 21, 22, 23 where a significant proportion of the population will have previously experienced an acute adenovirus infection and developed neutralizing immunity against common HAdV serotypes.24